
MIRM Stock Forecast & Price Target
MIRM Analyst Ratings
Bulls say
Mirum Pharmaceuticals is well-positioned for continued growth and success in the rare and orphan disease space, with its main product, Livmarli, showing strong momentum in sales and continued expansion into new indications. Additionally, the company has a robust pipeline of potential treatments for various liver diseases, with multiple near-term catalysts expected. Mirum's solid financials, including its high cash reserves and expected cash flow positivity in 2027, make it a promising investment opportunity for investors with a long-term outlook. However, risks exist, including potential delays in drug approvals and potential dilution. Despite these risks, Mirum is expected to continue its trajectory of success in the rare disease market.
Bears say
Mirum Pharmaceuticals is expected to face a challenging road to success, as its main product Livmarli is only approved for one indication and its other products are still in the clinical trial phase. The company's recent quarter was overshadowed by the disappointing feedback from the FDA regarding its potential submission for volixibat in PSC. Additionally, while the company's acquisition of Chenodal and Cholbam may expand its pipeline, it is not a guarantee for success in the highly competitive biopharmaceutical industry.
This aggregate rating is based on analysts' research of Mirum Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIRM Analyst Forecast & Price Prediction
Start investing in MIRM
Order type
Buy in
Order amount
Est. shares
0 shares